ESMO 2018 | PALOMA-3: palbociclib and fulvestrant for HR-/HER+ metastatic breast cancer

Massimo Cristofanilli

Massimo Cristofanilli, MD, from Northwestern University Feinberg School of Medicine, Chicago, IL, discusses the PALOMA-3 study (NCT01942135) of palbociclib combined with fulvestrant for HR-/HER+ metastatic disease after endocrine failure. This video was recorded at the breast cancer press briefing at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany, which presented the latest updates for three major Phase III clinical trials.

Share this video